AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -18.60% | 32.42% | -8.17% | 3.39% | -15.98% |
| Total Depreciation and Amortization | 15.96% | 16.75% | -24.47% | 11.52% | 8.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -805.75% | 53.97% | -187.10% | 300.93% | -77.05% |
| Change in Net Operating Assets | 56.20% | 16.74% | -243.83% | 342.03% | 19.01% |
| Cash from Operations | -14.71% | 43.42% | -54.38% | 51.62% | -8.81% |
| Capital Expenditure | -39.49% | 47.20% | -51.02% | -4.10% | -53.61% |
| Sale of Property, Plant, and Equipment | -50.00% | 166.67% | -- | -100.00% | 800.00% |
| Cash Acquisitions | 87.16% | 5.86% | 16.77% | -22.85% | 26.24% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -112.85% | -611.43% | 85.82% | 17.13% | -157.24% |
| Cash from Investing | -62.50% | -23.93% | 27.74% | 5.08% | -68.24% |
| Total Debt Issued | -100.28% | 527.27% | -187.50% | -154.66% | -41.40% |
| Total Debt Repaid | -2,544.79% | 95.45% | -2,166.67% | 19.13% | -35.29% |
| Issuance of Common Stock | -40.00% | -56.52% | 360.00% | 25.00% | -50.00% |
| Repurchase of Common Stock | 92.48% | -4,607.69% | 31.58% | -533.33% | 99.38% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 99.97% | -- | -- | -16,010.00% | 99.70% |
| Other Financing Activities | 100.00% | 75.51% | -9,700.00% | -50.00% | -101.92% |
| Cash from Financing | -1,070.79% | 108.14% | -58.32% | -500.19% | 119.14% |
| Foreign Exchange rate Adjustments | 150.00% | -550.00% | 133.33% | -141.38% | 16.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -244.82% | 176.24% | -327.29% | -42.58% | 922.07% |